Tag Archive for: ADC technology platform

Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024

Ladenburg, Germany, 6 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs) will be presenting first efficacy data on its Phase I clinical trial with ATAC candidate HDP-101 as well as preclinical data on other drug candidates from its proprietary ADC technology platform at the American […]